ClinicalTrials.gg
TerminatedNCT05581199Updated Aug 11, 2026

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

A Phase 2 interventional study of Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly and Batoclimab 340 mg SC weekly in Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Immunovant Sciences GmbH. Terminated at 98 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Enrollment
18th of 42
94 · median 74
Started
2022
with 4 others
Phase 2
16 of 55
2 open now
Registered
33rd of 55
by date
Lead sponsor
3 of 55
Immunovant Sciences GmbH

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 18th largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2022, is one of 16 in phase 2, and was the 33rd registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The total study duration will be up to approximately 109 weeks. Eligible participants will be assigned to one of four cohorts based upon their baseline CIDP treatment (Cohorts A and D - immunoglobulin [Ig] or plasma exchange [PLEX]; Cohort B - corticosteroids; Cohort C - naive or untreated in previous 3-24 months) and whether they meet diagnosis according to the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria (Cohorts A, B, and C) or clinical criteria only (Cohort D) at the time of screening.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy

Keywords

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • IMVT-1401
  • Monoclonal antibody
  • Autoimmune disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Cohorts:

  1. Are >= 18 years at the Screening Visit.
  2. Have met clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Clinical criteria for typical CIDP and variants are as follows (either criterion must be met):

    1. Typical CIDP: All the following:

      • Progressive or relapsing, symmetric, proximal, and distal muscle weakness of upper and lower limbs, and sensory involvement of at least two limbs (at any point in the disease course)
      • Developing over at least 8 weeks
      • Absent or reduced tendon reflexes in all limbs
    2. CIDP variants: One of the following, but otherwise as in typical CIDP (tendon reflexes may be normal in unaffected limbs):

      • Multifocal CIDP: documented sensory loss and muscle weakness in a multifocal pattern, usually asymmetric, upper limb predominant
      • Focal CIDP: sensory loss and muscle weakness in only one limb
      • Motor CIDP: motor symptoms and signs without sensory involvement

    Cohorts A and B:

  3. Have electrodiagnostic test results supporting the diagnosis of CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP; for Cohorts A and B, either criterion must be met:

    1. Motor nerve conduction criteria strongly supportive of demyelination.
    2. Motor nerve conduction criteria weakly supportive of demyelination and 2 or more of the following additional diagnostic criteria:

      • Objective improvement to an empiric trial of therapy with immunoglobulin treatment, plasma exchange (PLEX), or .
      • Diagnostic imaging by ultrasound or magnetic resonance imaging (MRI) supporting the diagnosis of CIDP by demonstrating nerve enlargement.
      • Cerebrospinal fluid (CSF) demonstrating albuminocytologic dissociation (i.e., elevated CSF protein level [defined as > 70 milligrams per deciliter {mg/dL} or > 10 mg/dL greater than years of age for those aged 60 years and over] with normal CSF white blood cell [WBC] level).
      • Nerve demonstrating features supporting the diagnosis of CIDP, such as edema, demyelination, and/or onion bulb formation.

    Cohort C only:

  4. Have a diagnosis of CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP based on clinical criteria and motor nerve conduction criteria strongly supportive of demyelination (i.e., motor nerve conduction criteria weakly supportive of demyelination is insufficient diagnostic evidence for admission to Cohort C).

    Cohort D only:

  5. Have met only clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Either inclusion criterion 2(a) or 2(b) must be met.

Additional inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion Criteria:

All Cohorts:

  1. Have current or prior history of immunoglobulin M (IgM) paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.
  2. Have Distal CIDP, Sensory CIDP or are suspected of having a diagnosis of auto-immune nodopathy in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP.
  3. Have polyneuropathy of causes other than CIDP including but not limited to:

    1. Multifocal motor neuropathy
    2. Hereditary demyelinating neuropathy
    3. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS)
    4. Lumbosacral radiculoplexus neuropathy
    5. Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies
    6. Drug- or toxin-induced
  4. Have diabetes mellitus (DM) and meets any of the following criteria:

    1. Does not meet inclusion criteria 2(a) and 3(a).
    2. In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP.
    3. In the opinion of the Investigator, there is evidence of poorly controlled DM at screening.
  5. Have a history of myelopathy or evidence of central demyelination.
  6. Are receiving chronic oral monotherapy at a dose > 40 mg/day prednisolone/prednisone or its equivalent at the Screening Visit.
  7. Are receiving chronic oral corticosteroid at a dose > 10 mg/day prednisolone/prednisone or equivalent in combination with immunoglobulin therapy or PLEX at the Screening Visit.

Additional exclusion criteria are defined in the protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Treatment Period 1: Cohort A, Dose 1

    Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly

  • Experimental
    Treatment Period 1: Cohort A, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Treatment Period 1: Cohort B, Dose 1

    Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly

  • Experimental
    Treatment Period 1: Cohort B, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Treatment Period 1: Cohort C, Dose 1

    Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly

  • Experimental
    Treatment Period 1: Cohort C, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Treatment Period 1: Cohort D, Dose 1

    Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly

  • Experimental
    Treatment Period 1: Cohort D, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Withdrawal Period 2: Cohort A, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Withdrawal Period 2: Cohort A, Placebo

    Drug: Placebo

  • Experimental
    Withdrawal Period 2: Cohort B, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Withdrawal Period 2: Cohort B, Placebo

    Drug: Placebo

  • Experimental
    Withdrawal Period 2: Cohort C, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Withdrawal Period 2: Cohort C, Placebo

    Drug: Placebo

  • Experimental
    Withdrawal Period 2: Cohort D, Dose 2

    Drug: Batoclimab 340 mg SC weekly

  • Experimental
    Withdrawal Period 2: Cohort D, Placebo

    Drug: Placebo

  • Experimental
    LTE Period: With Relapse in Period 2: Dose 1 and Dose 2

    Participants will receive Dose 1 for the initial 4 weeks only and Dose 2 for the remaining 48 weeks.

    Drug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly · Drug: Batoclimab 340 mg SC weekly

  • Experimental
    LTE Period: Without Relapse in Period 2: Dose 2

    Participants will receive Dose 2 for all 52 weeks.

    Drug: Batoclimab 340 mg SC weekly

Interventions

06

What researchers measure

Primary outcomes

  1. Period 2, Cohort A: Proportion of participants who remain relapse-free at Week 36

    Relapse is defined as a worsening (increase) of \>=1 point on adjusted inflammatory neuropathy cause and treatment (AdjINCAT) score at any time point during Period 2 relative to Period 2 Baseline which is sustained at a Follow-Up visit 1 week later. The INCAT disability scale is a widely used and validated efficacy assessment of neurologic dysfunction in CIDP. Upper and lower limb dysfunction are each separately assessed on a scale of 0-5 and results are summed together for a total composite score of 0-10. Higher scores represent greater disability. The Adj INCAT disability score is identical to INCAT disability score with exception that changes in upper limb function from 0 (normal) to 1 (minor symptoms) and vice versa are excluded since minor symptoms in the fingers, which are implied by an upper limb score of 1, are not considered clinically significant in all participants. The Adj INCAT disability score will be used for participant selection and measurement of clinical response.

    Time frame: Week 36

Secondary outcomes

  1. Period 2, Cohort A: Time to first relapse relative to Period 2 Baseline

    Time frame: Baseline (Week 12) to Week 36

  2. Period 2, Cohort A: Change from Period 2 Baseline in Adj INCAT score

    Time frame: Baseline (Week 12) and up to Week 36

  3. Period 2, Cohort A: Change from Period 2 Baseline in Inflammatory Rasch-built Overall Disability Scale (I-RODS)

    The I-RODS for immune-mediated peripheral neuropathies is a patient-based linearly weighted scale that captures activity and social participation limitations in patients with CIDP. The assessment consists of a 24-question instrument that addresses upper and lower limb tasks that range in difficulty from reading a book and eating to standing and running. Answers are scored on a scale of 0-2 (complete disability to no disability) and the raw scores are then transformed into a final score ranging from 0-100.

    Time frame: Baseline (Week 12) and up to Week 36

  4. Period 2, Cohort A: Change from Period 2 Baseline in Mean grip strength

    Mean Grip strength provides an objective, quantitative and immediate assessment of strength impairment. The Jamar dynamometer and the Martin vigorimeter are both commonly used to assess mean grip strength.

    Time frame: Baseline (Week 12) and up to Week 36

  5. Period 2, Cohort A: Change from Period 2 Baseline in Medical Research Council (MRC) Sum Score

    The MRC sum score is a standardized methodology for objectively assessing and reporting muscle function. Six muscle groups are assessed bilaterally, and each scored on a scale of 0 (no visible contraction) to 5 (normal) yielding a sum ranging from 0 (paralysis) to 60 (normal strength). Higher scores indicate normal muscle strength.

    Time frame: Baseline (Week 12) and up to Week 36

  6. Period 2, Cohort A: Change from Period 2 Baseline in Overall Neuropathy Limitations Scale (ONLS)

    The ONLS is a scale that focuses on upper and lower limb functions and was designed to assess the limitations of participants with immune-mediated peripheral neuropathies. This scale is completed by adding the total of the arm grade from zero point (less limitation) to 5 points (most limitation) and leg grade from zero point (less limitation) to 7 points (more limitation) yielding a total score of 0 (no disability) to 12 (maximum disability). Lower values in the ONLS indicate a better clinical condition.

    Time frame: Baseline (Week 12) and up to Week 36

  7. Period 2, Cohorts A and B combined: Change from Period 2 Baseline in Adj INCAT score

    Time frame: Baseline (Week 12) and up to Week 36

  8. Period 2, Cohorts A and B combined: Change from Period 2 Baseline in I-RODS

    Time frame: Baseline (Week 12) and up to Week 36

  9. Period 2, Cohorts A and B combined: Change from Period 2 Baseline in Mean Grip Strength

    Time frame: Baseline (Week 12) and up to Week 36

  10. Period 2, Cohorts A and B combined: Change from Period 2 Baseline in MRC sum score

    Time frame: Baseline (Week 12) and up to Week 36

  11. Period 2, Cohorts A and B combined: Change from Period 2 Baseline in ONLS

    Time frame: Baseline (Week 12) and up to Week 36

  12. Period 2, Cohorts A, B, and C: Proportion of participants who remain relapse-free at Week 36

    Time frame: Week 36

07

Study locations

98 sites
  • Site Number - 1603
    Scottsdale, Arizona 85028, United States
  • Site Number - 1634
    Los Angeles, California 90033-5330, United States
  • Site Number - 1625
    Aurora, Colorado 80045, United States
  • Site Number - 1621
    New Haven, Connecticut 06519, United States
  • Site Number - 1629
    Orlando, Florida 32806-5411, United States
  • Site Number - 1617
    Ormond Beach, Florida 32174, United States
  • Site Number - 1620
    Port Charlotte, Florida 33952, United States
  • Site Number - 1633
    Rockledge, Florida 32955, United States
  • Site Number - 1604
    St. Petersburg, Florida 33713, United States
  • Site Number - 1602
    Kansas City, Kansas 66160, United States
  • Site Number - 1611
    Nicholasville, Kentucky 40356, United States
  • Site Number - 1605
    New York, New York 10032, United States
  • Site Number - 1610
    Charlotte, North Carolina 28207, United States
  • Site Number - 1614
    Portland, Oregon 97239, United States
  • Site Number - 1623
    Philadelphia, Pennsylvania 19104, United States
  • Site Number - 1624
    Philadelphia, Pennsylvania 19104, United States
  • Site Number -1601
    Austin, Texas 78759, United States
  • Site Number - 1606
    Houston, Texas 77030, United States
  • Site Number - 1628
    San Antonio, Texas 78229, United States
  • Site Number - 1632
    Seattle, Washington 98195-0001, United States
  • Site Number - 1613
    Milwaukee, Wisconsin 53226-3548, United States
  • Site Number - 7753
    Rosario, Santa Fe Province S2000BZL, Argentina
  • Site Number - 7751
    Rosario, Santa Fe Province S2000DTP, Argentina
  • Site Number - 7752
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Site Number - 7750
    Buenos Aires, C1199ABB, Argentina
  • Site Number - 4681
    Ghent, Oost-Vlaanderen 09000, Belgium
  • Site Number - 4680
    Leuven, Vlaams Brabant 03000, Belgium
  • Site Number - 9103
    Brasília, Federal District 70200-730, Brazil
  • Site Number - 9101
    Curitiba, Paraná 81210-310, Brazil
  • Site Number - 9100
    Ribeirão Preto, São Paulo 14048-900, Brazil
  • Site Number - 9105
    São Paulo, 01409-000, Brazil
  • Site Number - 9111
    Sofia, Sofia-Grad 01527, Bulgaria
  • Site Number - 9110
    Sofia, Sofia-Grad 01606, Bulgaria
  • Site Number - 9112
    Pleven, 05800, Bulgaria
  • Site Number - 2600
    Edmonton, Alberta T6J 1M3, Canada
  • Site Number - 2603
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Site Number - 4740
    Copenhagen, 02100, Denmark
  • Site Number - 3241
    Turku, Southwest Finland 20520, Finland
  • Site Number - 6705
    Bochum, North Rhine-Westphalia 44791, Germany
  • Site Number - 6702
    Leipzig, Saxony 04103, Germany
  • Site Number - 6706
    Berlin, 10117, Germany
  • Site Number - 6341
    Pátrai, Achaïa 265 04, Greece
  • Site Number - 6344
    Athens, Attica 115 25, Greece
  • Site Number - 6345
    Athens, Attica 115 28, Greece
  • Site Number - 6343
    Alexandroupoli, Evros 68100, Greece
  • Site Number - 6342
    Heraklion, Irakleio 715 00, Greece
  • Site Number - 6346
    Ioannina, 455 00, Greece
  • Site Number - 6347
    Larissa, 41110, Greece
  • Site Number - 6302
    Gussago, Brescia 25084, Italy
  • Site Number - 6305
    Bologna, Emilia-Romagna 40139, Italy
  • Site Number - 6309
    Rome, Lazio 00133, Italy
  • Site Number - 6306
    Rome, Lazio 00189, Italy
  • Site Number - 6301
    Bergamo, Lombardy 24127, Italy
  • Site Number - 6307
    Milan, Lombardy 20132, Italy
  • Site Number - 6303
    Pisa, Tuscany 56126, Italy
  • Site Number - 6308
    Siena, Tuscany 53100, Italy
  • Site Number - 6300
    Pavia, 27100, Italy
  • Site Number - 6491
    Oslo, 00424, Norway
  • Site Number - 3207
    Poznan, Greater Poland Voivodeship 61-731, Poland
  • Site Number - 3211
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-065, Poland
  • Site Number - 3203
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Site Number - 3208
    Krakow, Lesser Poland Voivodeship 30-688, Poland
  • Site Number - 3209
    Krakow, Lesser Poland Voivodeship 31-202, Poland
  • Site Number - 3210
    Lublin, Lublin Voivodeship 20-064, Poland
  • Site Number - 3206
    Lublin, Lublin Voivodeship 20-701, Poland
  • Site Number - 3202
    Mazurki, Lublin Voivodeship 20-093, Poland
  • Site Number - 3205
    Gdansk, Pomeranian Voivodeship 80-803, Poland
  • Site Number - 3201
    Katowice, Silesian Voivodeship 40-123, Poland
  • Site Number - 3742
    Senhora da Hora, Porto District 4464-513, Portugal
  • Site Number - 3745
    Vila Nova de Gaia, Porto District 4434-502, Portugal
  • Site Number - 3743
    Almada, Setúbal District 2805-267, Portugal
  • Site Number - 3741
    Lisbon, 1300-344, Portugal
  • Site Number - 3744
    Porto, 4099-001, Portugal
  • Site Number - 8406
    Bucharest, Bucharest 41914, Romania
  • Site Number - 8401
    Târgu Mureş, Mureș County 540136, Romania
  • Site Number - 8403
    Timișoara, Timiș County 300736, Romania
  • SIte Number - 8400
    Constanța, 900591, Romania
  • Site Number - 8501
    Belgrade, 11000, Serbia
  • Site Number - 8502
    Belgrade, 11000, Serbia
  • Site Number - 8500
    Niš, 18000, Serbia
  • Site Number - 8503
    Novi Sad, 21000, Serbia
  • Site Number - 8600
    Liptovský Mikuláš, 031 23, Slovakia
  • Site Number - 8601
    Martin, 036 01, Slovakia
  • Site Number - 8603
    Prešov, 081 81, Slovakia
  • Site Number - 8602
    Trnava, 91775, Slovakia
  • Site Number - 9901
    Seoul, 02841, South Korea
  • Site Number - 9900
    Seoul, 06351, South Korea
  • Site Number - 3701
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Site Number - 3704
    Sant Cugat del Vallès, Barcelona 08190, Spain
  • Site Number - 3700
    San Sebastián, Gipuzkoa 20014, Spain
  • Site Number - 3703
    Barcelona, 08025, Spain
  • Site Number - 4891
    Gothenburg, Västra Götaland County 413 45, Sweden
  • Site Number - 7405
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • Site Number - 7402
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Site Number - 7404
    Glasgow, Lanarkshire G51 4TF, United Kingdom
  • Site Number - 7403
    Preston, Lancashire PR2 9HT, United Kingdom
  • Site Number - 7401
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Site Number - 7400
    Manchester, M6 8HD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2026, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2022
First posted
Oct 14, 2022
StartActual
Dec 15, 2022
Primary completionActual
Jul 20, 2026
CompletionActual
Jul 20, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05581199
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Dec 15, 2022
Primary completion
Jul 20, 2026
Completion
Jul 20, 2026
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion